pipeline
HomeOur PipelineBiosimilar Candidates
Biosimilar Candidates
After clicking on the screen, please scroll down at the bottom or move the screen left or right.
| Candidate | Active Substance | Therapeutic Area | Cell Line Dev. | Process Dev. | Preclinical | Phase I | Phase III | Approval |
|---|---|---|---|---|---|---|---|---|
| RBS-001 Biosimilar | Aflibercept | nAMD etc. | ||||||
| RBS-003 Biosimilar | Pembrolizumab | Oncology | ||||||
| RBS-007 Biosimilar | Nivolumab | Oncology | ||||||
| RBS-002 Biosimilar | Dupilumab | Inflammatory | ||||||
| RBS-004 Biosimilar | Vedolizumab | IBD | ||||||
| RBS-005 Biosimilar | Daratumumab | Oncology | ||||||
| RBS-008 Biosimilar | Secukinumab | Inflammatory | ||||||
| RBS-009 Biosimilar | Atezolizumab | Oncology | ||||||
-
Indication
nAMDMolecular Substance
Fusion ProteinMechanism of Action
VEGFR and PIGF InhibitorsOriginal Developer
Regeneron PharmaceuticalsPatent Expiration
2027
-
Indication
Non-small cell lung cancerMolecular Substance
Fusion ProteinMechanism of Action
PD-1 InhibitorOriginal Developer
MerckPatent Expiration
2028
-
Indication
OncologyMolecular Substance
mAbMechanism of Action
PD-1 InhibitorOriginal Developer
BMSPatent Expiration
2029
- COPYRIGHT (C) 2022 Rophibio, Inc. ALL RIGHT RESERVED. DESIGN BY THREEWAY.
- Privacy Policy